Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
Cancer Biol Ther. 2010 Aug 1;10(3):211-8. doi: 10.4161/cbt.10.3.12539. Epub 2010 Aug 11.
Colon cancer, the second leading cause of cancer-related mortality worldwide, originates from the malignant transformation of intestinal epithelial cells. The intestinal epithelium undergoes a highly organized process of rapid regeneration along the crypt-villus axis, characterized by proliferation, migration, differentiation and apoptosis, whose coordination is essential to maintaining the mucosal barrier. Disruption of these homeostatic processes predisposes cells to mutations in tumor suppressors or oncogenes, whose dysfunction provides transformed cells an evolutionary growth advantage. While sequences of genetic mutations at different stages along the neoplastic continuum have been established, little is known of the events initiating tumorigenesis prior to adenomatous polyposis coli (APC) mutations. Here, we examine a role for the corruption of homeostasis induced by silencing novel tumor suppressors, including the intestine-specific transcription factor CDX2 and its gene target guanylyl cyclase C (GCC), as early events predisposing cells to mutations in APC and other sequential genes that initiate colorectal cancer. CDX2 and GCC maintain homeostatic regeneration in the intestine by restricting cell proliferation, promoting cell maturation and adhesion, regulating cell migration and defending the intestinal barrier and genomic integrity. Elimination of CDX2 or GCC promotes intestinal tumor initiation and growth in aged mice, mice carrying APC mutations or mice exposed to carcinogens. The roles of CDX2 and GCC in suppressing intestinal tumorigenesis, universal disruption in their signaling through silencing of hormones driving GCC, and the uniform overexpression of GCC by tumors underscore the potential value of oral replacement with GCC ligands as targeted prevention and therapy for colorectal cancer.
结肠癌是全球癌症相关死亡率的第二大主要原因,源于肠上皮细胞的恶性转化。肠上皮细胞沿着隐窝-绒毛轴经历一个高度组织化的快速再生过程,其特征是增殖、迁移、分化和凋亡,这些过程的协调对于维持黏膜屏障至关重要。这些内稳态过程的破坏使细胞容易发生肿瘤抑制基因或癌基因的突变,这些基因的功能障碍为转化细胞提供了进化上的生长优势。虽然已经确定了肿瘤连续体不同阶段的遗传突变序列,但在 APC 突变之前引发肿瘤发生的事件知之甚少。在这里,我们研究了沉默新的肿瘤抑制因子(包括肠道特异性转录因子 CDX2 和其基因靶标鸟苷酸环化酶 C (GCC))引起的内稳态紊乱在 APC 和其他启动结直肠癌的序贯基因的突变之前对细胞的易感性中的作用。CDX2 和 GCC 通过限制细胞增殖、促进细胞成熟和黏附、调节细胞迁移以及保护肠屏障和基因组完整性来维持肠道的稳态再生。在老年小鼠、携带 APC 突变的小鼠或暴露于致癌剂的小鼠中消除 CDX2 或 GCC 会促进肠道肿瘤的起始和生长。CDX2 和 GCC 在抑制肠道肿瘤发生中的作用、通过沉默驱动 GCC 的激素普遍破坏其信号转导以及肿瘤中 GCC 的一致过度表达突出了通过口服 GCC 配体作为结直肠癌的靶向预防和治疗的潜在价值。